Cobimetinib

CHEMBL2146883 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
531.3 g/mol
LogP
3.9
Phase
4

A targeted cancer therapy that blocks a specific protein (MEK) involved in cell growth signaling pathways. It is often used in combination with other agents to treat certain types of cancer, including melanoma.

Peso molecular

531,3000 g/mol

LogP

3,90

TPSA

64,60 Ų

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Mecanismo de acción

Inhibits MEK1 and/or MEK2 kinases in the RAS/MAPK signaling pathway, blocking the transmission of growth signals that promote cancer cell proliferation and survival.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Inhibits MEK1 and/or MEK2 kinases in the RAS/MAPK signaling pathway, blocking the transmission of growth signals that promote cancer cell proliferation and survival.

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1

InChI

InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1

Molecular Formula

C21H21F3IN3O2

HBD / HBA

3 / 7

Enlaces Rotables

4

Átomos Pesados

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

A targeted cancer therapy that blocks a specific protein (MEK) involved in cell growth signaling pathways. It is often used in combination with other agents to treat certain types of cancer, including melanoma.

Inhibits MEK1 and/or MEK2 kinases in the RAS/MAPK signaling pathway, blocking the transmission of growth signals that promote cancer cell proliferation and survival.

Yes, Cobimetinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2146883. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 16222096. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.